Potential implications of COVID-19 in non-alcoholic fatty liver disease.
作者信息
Prins Grietje H, Olinga Peter
机构信息
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
出版信息
Liver Int. 2020 Oct;40(10):2568. doi: 10.1111/liv.14484. Epub 2020 May 25.
Abstract
摘要
相似文献
1
Potential implications of COVID-19 in non-alcoholic fatty liver disease.2019冠状病毒病对非酒精性脂肪性肝病的潜在影响。
Liver Int. 2020 Oct;40(10):2568. doi: 10.1111/liv.14484. Epub 2020 May 25.
2
Author response to Letter to the Editor: Potential implications of COVID-19 in non-alcoholic fatty liver disease.作者对致编辑的信的回复：2019冠状病毒病对非酒精性脂肪性肝病的潜在影响
Liver Int. 2020 Oct;40(10):2569-2570. doi: 10.1111/liv.14564. Epub 2020 Jul 5.
3
Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time.非酒精性脂肪性肝病与 COVID-19：双重疫情夹击
Medicina (Kaunas). 2021 Oct 3;57(10):1057. doi: 10.3390/medicina57101057.
4
Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD).在新冠疫情时代锻炼：对非酒精性脂肪性肝病（NAFLD）的影响。
BMJ Open Gastroenterol. 2021 Jun;8(1). doi: 10.1136/bmjgast-2020-000568.
5
Chronic liver disease-related mortality during the COVID-19 pandemic.新冠疫情期间慢性肝病相关死亡率
Eur J Intern Med. 2023 Dec;118:129-132. doi: 10.1016/j.ejim.2023.09.024. Epub 2023 Sep 29.
6
Lack of genetic evidence that fatty liver disease predisposes to COVID-19.缺乏脂肪肝疾病易引发2019冠状病毒病的基因证据。
J Hepatol. 2020 Sep;73(3):709-711. doi: 10.1016/j.jhep.2020.05.015. Epub 2020 May 20.
7
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.代谢功能障碍相关脂肪性肝病且纤维化评分升高的患者感染新型冠状病毒肺炎后出现重症的风险。
Gut. 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611. Epub 2020 May 15.
8
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
9
Vitamin D and Wellbeing beyond Infections: COVID-19 and Future Pandemics.维生素D与感染之外的健康：新冠疫情及未来大流行
J Am Coll Nutr. 2021 Jan;40(1):41-42. doi: 10.1080/07315724.2020.1786302. Epub 2020 Aug 14.
10
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者中COVID-19病情更严重的危险因素
Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29.
引用本文的文献
1
Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.代谢功能障碍相关脂肪性肝病对BNT162b2针对严重急性呼吸综合征冠状病毒2奥密克戎变种免疫原性的影响。
J Gastroenterol Hepatol. 2024 Nov;39(11):2386-2393. doi: 10.1111/jgh.16716. Epub 2024 Aug 17.
2
Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients?COVID-19 中的胰腺和肝脏损伤：非酒精性脂肪性肝病患者的预后更差？
Biomedicines. 2024 Jan 26;12(2):283. doi: 10.3390/biomedicines12020283.
3
Association between biochemical and hematologic factors with COVID-19 using data mining methods.运用数据挖掘方法分析生物化学和血液学因素与 COVID-19 的关系。
BMC Infect Dis. 2023 Dec 21;23(1):897. doi: 10.1186/s12879-023-08676-0.
4
Long-term multiple metabolic abnormalities among healthy and high-risk people following nonsevere COVID-19.非重症 COVID-19 后健康人群和高危人群的长期多重代谢异常。
Sci Rep. 2023 Aug 31;13(1):14336. doi: 10.1038/s41598-023-41523-5.
5
Metabolic-associated fatty liver disease and liver fibrosis scores as COVID-19 outcome predictors: a machine-learning application.代谢相关脂肪性肝病和肝纤维化评分作为 COVID-19 结局预测因子：机器学习应用。
Intern Emerg Med. 2023 Oct;18(7):2063-2073. doi: 10.1007/s11739-023-03316-6. Epub 2023 Jun 3.
6
MELD-Na score, Acute Physiologic and Chronic Health Evaluation II score, and SOFA score and their association with mortality in critically ill COVID-19 patients with liver injury: A retrospective single-center study.终末期肝病模型钠评分、急性生理与慢性健康状况评分系统II评分及序贯器官衰竭评估评分及其与新冠肺炎合并肝损伤重症患者死亡率的关联：一项回顾性单中心研究
Int J Crit Illn Inj Sci. 2022 Oct-Dec;12(4):222-228. doi: 10.4103/ijciis.ijciis_29_22. Epub 2022 Dec 26.
7
Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.COVID-19 对代谢相关脂肪性肝病患者的临床影响。
World J Gastroenterol. 2023 Jan 21;29(3):487-502. doi: 10.3748/wjg.v29.i3.487.
8
Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.新型冠状病毒肺炎（COVID-19）在原有肝脏疾病基础上致新发肝损伤的风险-文献复习。
Medicina (Kaunas). 2022 Dec 28;59(1):62. doi: 10.3390/medicina59010062.
9
Pancreatic Steatosis Evaluated by Automated Volumetric CT Fat Fraction of the Pancreas: Association with Severity in COVID-19 Pneumonia.胰腺脂肪变性的 CT 自动容积测量脂肪分数评估：与 COVID-19 肺炎严重程度的关系。
Tomography. 2022 Nov 24;8(6):2806-2814. doi: 10.3390/tomography8060234.
10
An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic.加拿大肝脏研究协会关于2019冠状病毒病大流行期间肝病管理的最新情况。
Can Liver J. 2020 Nov 17;3(4):309-321. doi: 10.3138/canlivj-2020-0013. eCollection 2020 Fall.
本文引用的文献
1
Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis.2019 年冠状病毒病与慢性肝病的流行情况：一项荟萃分析。
Liver Int. 2020 Jun;40(6):1316-1320. doi: 10.1111/liv.14465. Epub 2020 Apr 24.
2
Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study.COVID-19 住院非 ICU 患者的临床特征与肝损伤：一项回顾性研究。
Liver Int. 2020 Jun;40(6):1321-1326. doi: 10.1111/liv.14449. Epub 2020 Apr 12.
3
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
4
Liver injury during highly pathogenic human coronavirus infections.高致病性人冠状病毒感染期间的肝损伤。
Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435. Epub 2020 Mar 30.
5
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.大鼠和人类的慢性肝损伤会上调新型酶血管紧张素转换酶2。
Gut. 2005 Dec;54(12):1790-6. doi: 10.1136/gut.2004.062398. Epub 2005 Sep 15.
Zotero 插件